Candel Therapeutics Inc (NASDAQ: CADL) is 489.12% higher on its value in year-to-date trading and has touched a low of $1.10 and a high of $14.60 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CADL stock was last observed hovering at around $8.63 in the last trading session, with the day’s gains setting it 0.17%.
Currently trading at $8.80, the stock is 38.51% and 57.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.1 million and changing 1.97% at the moment leaves the stock 42.69% off its SMA200. CADL registered 673.21% gain for a year compared to 6-month loss of 51.66%. The firm has a 50-day simple moving average (SMA 50) of $5.5375 and a 200-day simple moving average (SMA200) of $6.1321.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 71.83% gain in the last 1 month and extending the period to 3 months gives it a 23.71%, and is 31.21% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 23.64% over the week and 22.12% over the month.
Candel Therapeutics Inc (CADL) has around 42 employees, a market worth around $399.09M and $0.00M in sales. Distance from 52-week low is 700.00% and -39.73% from its 52-week high.
The EPS is expected to shrink by -21.37% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
74.0 institutions hold shares in Candel Therapeutics Inc (CADL), with institutional investors hold 32.37% of the company’s shares. The shares outstanding are 32.13M, and float is at 26.22M with Short Float at 17.42%. Institutions hold 22.53% of the Float.
The top institutional shareholder in the company is NORTHPOND VENTURES, LLC with over 1.94 million shares valued at $12.0 million. The investor’s holdings represent 6.628 of the CADL Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 0.82 million shares valued at $5.1 million to account for 2.819 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 0.82 million shares representing 2.8035 and valued at over $5.08 million, while STATE STREET CORP holds 1.6193 of the shares totaling 0.47 million with a market value of $2.93 million.
Candel Therapeutics Inc (CADL) Insider Activity
The most recent transaction is an insider purchase by Manning Paul B, the company’s Director. SEC filings show that Manning Paul B bought 1,250,000 shares of the company’s common stock on Dec 16 ’24 at a price of $6.00 per share for a total of $7.5 million. Following the purchase, the insider now owns 1.3 million shares.
Candel Therapeutics Inc disclosed in a document filed with the SEC on Nov 29 ’24 that Tyagarajan Seshu (Chief Technology Officer) sold a total of 20,392 shares of the company’s common stock. The trade occurred on Nov 29 ’24 and was made at $4.56 per share for $92898.0. Following the transaction, the insider now directly holds 0.13 million shares of the CADL stock.
Still, SEC filings show that on Nov 29 ’24, Tak Paul Peter (Chief Executive Officer) disposed off 48,847 shares at an average price of $4.56 for $0.22 million. The insider now directly holds 294,788 shares of Candel Therapeutics Inc (CADL).
